DKN-01 +/- paclitaxel
Endometrial cancer overview
Endometrial cancer is the most common gynecologic cancer. The American Cancer Society estimates that about 66,000 new cases of endometrial cancer will be diagnosed in 2021 and that over 12,000 women will die of endometrial cancer.
Patients with endometrial cancer have a high frequency of mutations in a protein known as beta-catenin. These beta-catenin mutations are often driver mutations leading to high expression of DKK1, rapid disease progression, and poor outcomes. DKN-01 has demonstrated single agent activity in endometrial cancer patients, including a patient with a complete response. The activity of DKN-01 in endometrial cancer was strongest in patients whose tumors were expressing high levels of DKK1.